Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Digestive Disease Week Annual Conference, held in San Diego, CA on May 18th -21st.

Algernon Pharmaceuticals to Present Data on Its Inflammatory Bowel Disease Research Program at The Digestive Disease Week Annual Conference

Results of Nash’s recently announced Crohn's study demonstrated significant improvements in multiple measurements for both NP-120 and NP-178 including:

Improved body weight, stool consistency, occult positivity, colon length and weight and its ratios
5-ASA, the positive control reduced the histopathology severity score by 44.0% (p<0.01)
NP-120 (30 mg/kg) reduced the histopathology severity score by 45.1% (p<0.01)
NP-178 (160 mg/kg) reduced the histopathology severity score by 66.8% (p<0.001)

Results of Nash’s recently announced ulcerative colitis study demonstrated significant improvements in multiple measurements for both NP-120 and NP-178 including:

Both compounds improved body weight, stool consistency, occult positivity, colon length and weight and its ratios
5-ASA (100 mg/kg), the positive control and standard of care, reduced the histopathology severity score by 83.5% (p<0.0001)
NP-120 (30 mg/kg) reduced the histopathology severity score by 81.6% (p<0.0001)
NP-178 (160 mg/kg) reduced the histopathology severity score by 83.1% (p<0.0001)

The Digestive Disease Week Conference is one of the top 50 medical meetings in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. The conference is expected to attract worldwide gastroenterologists, clinical investigators, scientists and medical professionals related to the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

“We are very pleased to be presenting the data from our IBD research program at the upcoming Digestive Disease Week Conference”, said Christopher J. Moreau, CEO of Nash Pharmaceuticals. “It will be the first time that the Company will have an opportunity to present its findings to the global IBD research community.”

/////AMG